secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105029
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma Q2 net loss narrows to $7.0M; cash burn slows; ATH-1105 Phase 1 data support ALS development
--------------------------------------------------------------------------------

- Net loss of $7.0M ($0.18/sh) vs $26.9M ($0.70) in Q2 2024, driven by lower R&D and G&A spend.
- Cash, equivalents and investments $29.8M as of June 30, 2025, down from $51.3M at Dec 31, 2024.
- R&D expenses fell to $3.7M from $22.2M; G&A to $3.6M from $5.9M, reflecting cost reduction after LIFT-AD failure.
- Phase 1 trial of ATH-1105 (ALS) showed favorable safety, dose-proportional PK, and CNS penetration; preparation for future ALS trial ongoing.
- Company continues to explore strategic alternatives with Cantor Fitzgerald; fosgonimeton development paused.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017025105029/0000950170-25-105029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017025105029/atha-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer